Import from '@womanrx/ui'

Drew Barrymore Menopause: The Private-Clinic Pathway They Likely Used

What Drew Barrymore Actually Said, and Why It Matters

Drew Barrymore did not whisper about menopause. She said it out loud, on television, in front of millions of viewers. During segments on "The Drew Barrymore Show," she described waking in the night drenched in sweat, mood shifts she did not recognise in herself, and a body that felt unfamiliar. She named perimenopause. That act alone is clinically significant.

Why does a celebrity's candour show up in a medical article? Because research published in Menopause journal shows that fewer than 20% of women report receiving adequate information about perimenopause from their primary care provider, which means millions of women are being diagnosed with anxiety, depression, or insomnia when the root cause is fluctuating oestrogen. Public disclosure by a high-profile woman drives search behaviour, clinical conversations, and ultimately diagnosis. That is not trivial.

Barrymore was around 48 to 49 when she spoke about this. The median age of menopause in the United States is 51.4 years, which places her squarely in the perimenopause window, the two-to-ten-year transition that precedes the final menstrual period.

The Private-Clinic First Appointment: What Actually Happens

A woman at Barrymore's age and symptom profile, walking into a NAMS-certified menopause specialist or reproductive endocrinologist in a private clinic, would not simply get a blood test and a prescription. The first visit is a structured clinical encounter.

The Symptom Inventory

The clinician would use a validated tool. The Menopause Rating Scale (MRS) or the Greene Climacteric Scale quantifies somatic, psychological, and urogenital symptoms with a numerical score, creating a baseline to measure treatment response against. Hot flash frequency, severity, sleep architecture disruption, mood, libido, and any genitourinary symptoms are all documented.

For Barrymore specifically, the night sweats and mood shifts she described map directly onto vasomotor symptoms (VMS) and neuropsychological symptoms, both of which are oestrogen-sensitive and both of which respond to hormone therapy in the majority of women.

The Hormone Panel

Private clinics run a broader panel than a standard GP visit. Expect:

• FSH (follicle-stimulating hormone): elevated FSH, typically above 25 IU/L on two occasions 6 weeks apart, supports a perimenopause diagnosis, though ACOG confirms FSH alone is unreliable in perimenopause due to wide day-to-day variation
• Oestradiol (E2): typically low or erratic; <50 pg/mL on multiple draws supports declining ovarian reserve
• Testosterone (total and free): relevant for libido, energy, and mood, and systematically lower in women than men, with further decline across perimenopause
• DHEA-S: adrenal androgen, a precursor to sex hormones, declines with age
• TSH with reflex free T4: thyroid dysfunction is common in women in this age group and mimics perimenopause symptoms almost perfectly
• Full metabolic panel: fasting glucose, lipid panel, because oestrogen loss accelerates cardiovascular risk

The NAMS 2022 Hormone Therapy Position Statement makes clear that diagnosis of perimenopause is primarily clinical, not biochemical, but a private clinic uses the panel to rule out thyroid disease, anaemia, and adrenal dysfunction as competing explanations.

Bone Density Baseline

A private menopause clinic would almost certainly order or discuss a DEXA scan. Bone loss accelerates sharply in the two years before and three years after the final menstrual period, and Barrymore, at 48-49, is in exactly that window. If her DEXA showed a T-score between -1.0 and -2.5 (osteopenia), that finding alone strengthens the clinical case for hormone therapy.

Cardiovascular Risk Screen

Blood pressure, waist circumference, fasting lipids, and family history of premature cardiovascular disease. The reason: hormone therapy is most beneficial and least risky when initiated within 10 years of menopause or before age 60, the so-called "timing hypothesis" or "window of opportunity," supported by observational data from the Nurses' Health Study and the re-analysis of the WHI.

The Treatment Protocol She Was Most Likely Offered

Based on her age, symptom profile, and the current standard of care from a NAMS-certified specialist, the most likely protocol involves transdermal oestrogen plus micronized progesterone.

Transdermal Estradiol: Why This Route, Not a Pill

Oral oestrogen passes through the liver on first pass, raising triglycerides and clotting factors. Transdermal oestrogen bypasses the liver entirely. A systematic review in the BMJ found that transdermal oestradiol carries no measurable increase in venous thromboembolism risk, unlike oral preparations. For a woman in her late 40s with no personal VTE history, transdermal is now the default recommendation in most specialist clinics.

Typical starting doses: 0.025 mg/day to 0.05 mg/day via a twice-weekly patch, or equivalent gel (0.75 mg to 1.5 mg EstroGel daily). Most women with moderate-to-severe VMS require 0.05 mg/day to 0.1 mg/day to achieve symptom control.

Micronized Progesterone: Protecting the Uterus

Because Barrymore has not had a hysterectomy, she needs progestogen to protect the uterine lining from oestrogen-driven hyperplasia. ACOG and the Menopause Society both recommend micronized progesterone (Prometrium) as the preferred progestogen because it carries a more favourable cardiovascular and breast-risk profile than synthetic progestins. Typical dose: 100 mg nightly (continuous) or 200 mg for 12-14 days per cycle (sequential, if cycles are still present).

Testosterone: The Overlooked Piece

Private menopause clinics, unlike most NHS or insurance-driven practices, routinely assess and treat low testosterone in women. A 2019 global consensus statement published in the Journal of Sexual Medicine confirmed that testosterone therapy in postmenopausal and perimenopausal women improves sexual function, particularly low desire. Barrymore's candid comments about mood and feeling unlike herself may also reflect androgen decline, not just oestrogen loss.

Typical private-clinic prescription: testosterone cream or gel at 5-10% of the male dose, applied to the inner thigh or abdomen. No FDA-approved female formulation exists in the US as of 2025, so this is always off-label. The clinician monitors free testosterone at 3 months to ensure levels stay in the female physiological range.

Sleep and Mood: Not Always a Separate Referral

Many women arriving with mood symptoms are handed a psychiatry referral before anyone checks their hormones. A good menopause specialist does this differently. A 2021 study in JAMA Psychiatry found that perimenopausal women had a two- to three-times higher risk of a major depressive episode than premenopausal women, and that the risk is biologically driven by oestrogen fluctuation, not life stress alone. In that context, initiating hormone therapy first, and reassessing mood at 8-12 weeks, is clinically defensible.

The private-clinic framework for perimenopausal mood looks like this:

1. Rule out thyroid dysfunction (TSH) before attributing symptoms to perimenopause
2. Start transdermal oestradiol at therapeutic dose
3. Reassess mood at 8 and 12 weeks using PHQ-9 or GAD-7
4. If clinically significant depression persists despite adequate oestrogen, add or refer for SSRI/SNRI
5. Do not default to antidepressants before hormone therapy in a newly perimenopausal woman with no prior psychiatric history

This framework is not standard at most primary care practices. It is standard at a private menopause clinic.

Pregnancy, Contraception, and the Perimenopause Trap

This section applies to every woman reading this who still has a uterus and irregular periods.

Perimenopause does not equal infertility. Ovulation is erratic but it still happens. ACOG's Committee Opinion on Contraception for Midlife Women states that pregnancy, though rare, does occur in women in their late 40s and that contraception should be used until 12 consecutive months of amenorrhoea in women over 50, or 24 months in women under 50. The low-dose hormone therapy used for menopause symptoms does NOT provide contraception.

Contraception Options During Perimenopause

| Method | Notes for Perimenopausal Women | |---|---| | Levonorgestrel IUD (Mirena 52 mg) | Provides endometrial protection AND contraception; often used instead of oral progesterone | | Progestogen-only pill | Suitable if oestrogen is contraindicated; does not suppress ovulation reliably at this age | | Combined hormonal contraception | Can mask menopause transition; generally avoided after 50; not suitable in smokers over 35 | | Barrier methods | No contraindication; effectiveness depends on consistent use | | Tubal ligation / vasectomy | Permanent; appropriate if family is complete |

Hormone Therapy Is Not Contraception

The transdermal oestradiol doses used for symptom management (0.025 to 0.1 mg/day) are far below the doses needed to suppress ovulation. A woman using a 0.05 mg patch plus 100 mg micronized progesterone nightly can still conceive. A Mirena IUD elegantly solves two problems at once: it delivers local levonorgestrel to the uterus (protection against hyperplasia and contraception) while allowing systemic oestrogen to be added separately.

If Pregnancy Occurs While on HRT

Standard-dose HRT oestrogens are not classified teratogens, but hormone therapy is not indicated in pregnancy and should be stopped immediately if pregnancy is confirmed. Micronized progesterone in the first trimester is actually used therapeutically in some IVF and recurrent miscarriage protocols, but this is a specialist decision, not a reason to continue self-prescribed perimenopause HRT through a pregnancy. Confirm with your prescriber immediately.

Who This Protocol Is Right For, and Who Should Think Differently

Right For

• Women aged 45-55 with vasomotor symptoms (hot flashes, night sweats) affecting sleep or quality of life
• Perimenopausal women with new-onset low mood, brain fog, or joint pain without a clear alternative explanation
• Women with early bone density loss (osteopenia T-score between -1.0 and -2.5) seeking a non-bisphosphonate first option
• Women who have been dismissed with "it's just stress" by a GP and want a thorough specialist work-up

Proceed with Caution or an Alternative Plan

• Women with a personal history of oestrogen-receptor-positive breast cancer: ACOG states HRT is generally contraindicated in this group and non-hormonal options (SSNRIs, gabapentin, fezolinetant) should be explored first
• Women with untreated hypertension or active liver disease: transdermal oestrogen is preferred over oral, but cardiovascular stability should be established first
• Women with unexplained vaginal bleeding: requires endometrial evaluation before HRT initiation
• Women with a history of VTE or known thrombophilia: risk-benefit discussion with haematology input is required; transdermal oestrogen may still be possible but is not automatic

Life Stage Specifics

Reproductive years (under 40 with early menopause): Premature ovarian insufficiency (POI) affects approximately 1 in 100 women before age 40 and carries unique risks. HRT here is not optional for most women; it is cardiovascular and bone protection, and doses are often higher than standard menopausal HRT to replace what the ovaries would normally be producing.

Trying to conceive: Perimenopause and subfertility overlap. Reproductive endocrinology input is needed before starting HRT, because the same hormonal work-up informs fertility planning.

Postpartum: Postpartum oestrogen drop is physiological but can be severe. Postpartum thyroiditis, which affects 5-10% of women in the year after delivery, mimics perimenopausal symptoms. Rule this out first.

The Non-Hormonal Toolkit Private Clinics Also Use

Not every woman wants or can have hormone therapy. A good private clinic does not present HRT as the only answer.

Fezolinetant (Veoza)

Fezolinetant is the first non-hormonal, non-antidepressant drug approved specifically for moderate-to-severe vasomotor symptoms. It is a neurokinin B receptor antagonist that works at the thermoregulatory centre in the hypothalamus. The FDA approved fezolinetant (Veoza) in May 2023 based on the SKYLIGHT 1 and SKYLIGHT 2 trials, which showed a 60-65% reduction in VMS frequency versus placebo at 12 weeks. It is appropriate for women who cannot or choose not to use oestrogen.

SSNRIs and Gabapentin

• Venlafaxine 37.5-75 mg/day reduces hot flash frequency by approximately 60% in some trials
• Gabapentin 300 mg three times daily is effective for night sweats, particularly useful in women with concurrent sleep disruption
• Neither is specifically approved for VMS, so both are off-label prescriptions for this indication

Lifestyle Modifications With Actual Evidence

A 2023 randomised controlled trial published in Menopause journal (the MenSS trial) found that a structured cognitive behavioural therapy program reduced the problem rating of hot flashes and night sweats by 44% at 6 weeks compared to 16% in controls. This is not a soft option. CBT for menopause is a NICE-recommended intervention. Weight management also matters: adipose tissue generates heat during VMS episodes, and a BMI <27 is associated with lower VMS severity.

Monitoring: What Happens After the First Prescription

A responsible private clinic does not simply hand over a prescription and a repeat. The monitoring schedule for the first year of hormone therapy typically looks like this:

• 6-8 weeks: Symptom check, side-effect review (breast tenderness, bloating), blood pressure, and any spotting or bleeding assessment
• 3 months: Repeat free testosterone if prescribed; reassess mood with validated score; check that dose is therapeutic
• 6 months: Repeat lipid panel if baseline was abnormal; assess adherence and application technique for transdermal preparations
• 12 months: Full review including DEXA reassessment if baseline was abnormal; blood pressure; breast awareness review; shared decision-making on continuation

The Menopause Society recommends annual review and shared decision-making on duration, with no arbitrary time limit on HRT for women who are still symptomatic and have no contraindication.

The Evidence Gap: What We Do Not Know Yet

Women deserve honesty about where the evidence runs thin. Most of the large HRT trials, including the Women's Health Initiative, enrolled postmenopausal women with an average age of 63, not perimenopausal women in their late 40s. The WHI participants were, on average, 12 years past menopause when enrolled, which means the risk data does not map cleanly onto a woman aged 48 starting hormone therapy.

Testosterone therapy for women has a reasonable evidence base for sexual function, but long-term safety data beyond 2 years is sparse. Fezolinetant data beyond 52 weeks is not yet available from randomised trials. Bioidentical compounded hormones, often marketed at private wellness clinics, have no regulatory approval and no randomised trial data supporting superiority over approved preparations.

The honest clinical position: the approved, regulated hormone preparations have the best evidence. Custom compounded formulations may feel more "natural," but they carry manufacturing variability that regulated products do not.